#1 Clinical Trials Search in Europe

Vobramitamab Duocarmazine

Vobramitamab Duocarmazine is an innovative drug currently being studied in clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This article explores the ongoing research, potential benefits, and important information for patients considering participation in these trials.

Table of Contents

What is Vobramitamab Duocarmazine?

Vobramitamab Duocarmazine, also known as MGC018, is a new medication being studied for the treatment of metastatic castration-resistant prostate cancer (mCRPC)[1]. It is classified as an antibody-drug conjugate, which is a type of targeted therapy that combines an antibody with a cancer-fighting drug[1].

Medical Condition Treated

Vobramitamab Duocarmazine is being investigated for the treatment of metastatic castration-resistant prostate cancer. Let’s break down this term:

  • Metastatic: This means the cancer has spread from the prostate to other parts of the body.
  • Castration-resistant: This type of prostate cancer continues to grow even when the levels of testosterone in the body are reduced to very low levels.
  • Prostate cancer: A type of cancer that develops in the prostate gland, which is part of the male reproductive system.

This condition is typically challenging to treat, making new therapies like Vobramitamab Duocarmazine particularly important[1].

How Vobramitamab Duocarmazine Works

Vobramitamab Duocarmazine is designed to target a specific protein called B7-H3, which is often found on cancer cells[1]. The medication works in two steps:

  1. The antibody part of the drug (vobramitamab) attaches to the B7-H3 protein on cancer cells.
  2. Once attached, it delivers the cancer-fighting part of the drug (duocarmazine) directly to the cancer cells, aiming to kill them while minimizing damage to healthy cells.

Clinical Trial Details

A clinical trial called TAMARACK is currently underway to study Vobramitamab Duocarmazine[1]. This is a Phase 2 trial, which means it’s testing how well the drug works and how safe it is. Here are some key details about the trial:

  • It’s a randomized, open-label study, meaning participants are randomly assigned to different treatment groups, and both patients and doctors know which treatment is being given.
  • The trial is comparing two different dose levels of Vobramitamab Duocarmazine.
  • The main goal is to evaluate how effective the drug is at slowing down the progression of cancer, measured by something called Radiographic Progression Free Survival (rPFS)[1].

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria. Some key requirements include[1]:

  • Having confirmed prostate cancer that has spread to other parts of the body.
  • Having received previous treatment with certain types of prostate cancer drugs.
  • Not having certain other medical conditions that might interfere with the treatment.

It’s important to note that these are just a few of the criteria. A healthcare provider can provide more detailed information about eligibility.

Potential Benefits

The clinical trial aims to determine several potential benefits of Vobramitamab Duocarmazine, including[1]:

  • Slowing down the progression of cancer (measured by rPFS).
  • Reducing levels of prostate-specific antigen (PSA), a protein often elevated in prostate cancer.
  • Shrinking tumors (in patients with measurable disease).
  • Delaying the onset of bone-related complications.

Side Effects and Safety

As with any medication, Vobramitamab Duocarmazine may cause side effects. The clinical trial is carefully monitoring patients for any adverse events. Some areas of focus include[1]:

  • The frequency and severity of side effects.
  • How well patients tolerate the medication.
  • Any serious adverse events that may occur.
  • Whether the body develops antibodies against the drug (known as immunogenicity).

It’s important to remember that as this is an experimental drug, not all potential side effects may be known yet.

Dosage and Administration

In the TAMARACK clinical trial, Vobramitamab Duocarmazine is being tested at two different dose levels[1]:

  • 2.0 mg/kg given intravenously every 4 weeks
  • 2.7 mg/kg given intravenously every 4 weeks

The treatment is planned to continue for up to 26 cycles or 2 years, whichever comes first. It’s administered as a concentrate for solution for infusion, which means it’s given directly into the bloodstream through a vein[1].

Aspect Details
Study Name TAMARACK
Study Phase Phase 2
Study Design Randomized, Open-Label
Target Condition Metastatic Castration-Resistant Prostate Cancer
Drug Tested Vobramitamab Duocarmazine
Dose Levels 2.0 mg/kg and 2.7 mg/kg
Administration Intravenous, every 4 weeks
Primary Endpoint Radiographic Progression Free Survival (rPFS)
Key Secondary Endpoints PSA response, Objective Response Rate, Duration of Response, Safety
Treatment Duration Up to 26 cycles or 2 years, whichever comes first

FAQ

  • What is Vobramitamab Duocarmazine? Vobramitamab Duocarmazine is an antibody-drug conjugate being tested as a treatment for metastatic castration-resistant prostate cancer. It's designed to target cancer cells more specifically than traditional chemotherapy.
  • What is the main goal of the TAMARACK clinical trial? The main goal of the TAMARACK trial is to evaluate how effective Vobramitamab Duocarmazine is at two different dose levels. They're measuring this by looking at how long patients live without their cancer getting worse, which is called Radiographic Progression Free Survival.
  • Who can participate in this clinical trial? The trial is for patients with metastatic castration-resistant prostate cancer who have received one prior treatment with androgen receptor-targeted therapy. Participants must have at least one metastatic lesion and show tumor progression. There are other specific criteria that doctors will check to determine eligibility.
  • How is the drug administered in the trial? Vobramitamab Duocarmazine is given through an intravenous (IV) infusion every 4 weeks. The trial is testing two different dose levels: 2.0 mg/kg and 2.7 mg/kg.
  • What are the potential side effects of Vobramitamab Duocarmazine? While the specific side effects are still being studied, the trial is closely monitoring for any adverse events. Patients will be regularly checked for side effects, and the study will evaluate the overall tolerability of the drug at both dose levels.

Ongoing Clinical Trials on Vobramitamab Duocarmazine

  • Study of Vobramitamab Duocarmazine and Prednisone for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Belgium Czechia France Germany Italy Poland +1

Glossary

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC): A type of prostate cancer that has spread beyond the prostate to other parts of the body and continues to grow despite treatments that lower testosterone levels.
  • Vobramitamab Duocarmazine: An antibody-drug conjugate being studied for the treatment of mCRPC. It's designed to target cancer cells more specifically than traditional chemotherapy.
  • Radiographic Progression Free Survival (rPFS): The length of time during and after treatment that a patient lives without their cancer getting worse, as determined by imaging scans.
  • Prostate-Specific Antigen (PSA): A protein produced by the prostate gland. High levels in the blood can indicate prostate cancer or other prostate conditions.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Duration of Response (DoR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Symptomatic Skeletal Event (SSE): A complication of cancer that has spread to the bones, such as bone pain or fractures.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Anti-Drug Antibodies (ADA): Antibodies produced by the body's immune system in response to a drug, which can potentially affect the drug's effectiveness or safety.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.

References

  1. http://clinicaltrials.eu/trial/study-of-vobramitamab-duocarmazine-and-prednisone-for-patients-with-metastatic-castration-resistant-prostate-cancer/